Abstract. Sturge-Weber syndrome (SWS) is a rare neurocutaneous disorder whose etiology remains unclear. To investigate the genetic contribution underlying this disease, the genetic variants of a 4-generation family with a history of SWS was analyzed in the present study. SWS was diagnosed in 3 of the family members (II-1, III-11 and IV-6). Sanger sequencing was performed to identify mutations in G protein subunit αq (GNAQ) and RAS p21 protein activator 1 exons in the 3 patients with SWS and other unaffected family members. Notably, a non-synonymous single-nucleotide variant at codon 183 on exon 4 of the GNAQ gene was identified as the only pathogenic site. This variant generated a substitution of arginine (R) with glutamine and resulted in a change of function of the encoded protein. Evolutionary conservation analysis revealed that the mutated residue 183 (R) of GNAQ is highly conserved across several vertebrate species. Furthermore, an immunofluorescence staining assay demonstrated that the substitution of arginine with glutamine resulted in a change in the subcellular localization of the GNAQ recombinant protein in vitro. These findings may aid in the development of novel diagnostic markers and/or therapeutic targets for the treatment of patients with familial SWS.

Introduction

Sturge-Weber syndrome (SWS), also known as encephalofacial angiomatosis, is a congenital neurocutaneous disorder characterized by facial port-wine stains, ipsilateral occipital leptomeningeal angioma and/or abnormal blood vessels in the eyes, which predisposes patients to glaucoma (1). SWS occurs in male and female newborns, in 1/20,000 to 1/50,000 live births (2). Patients with SWS frequently develop migraines, seizures, stroke-like episodes, hemiparesis, visual problems and mental retardation (3). Furthermore, the majority of treatments for the neurological complications associated with SWS are symptomatic instead of radical. The etiology of SWS remains unclear; however, evidence from whole-genome sequencing suggests that somatic mutations in the G protein subunit αq (GNAQ) and RAS p21 protein activator 1 (RASA1) genes are causative factors of SWS and non-syndromic port-wine stains (4). Familial SWS is a rare genetic disorder that is dominantly inherited, which could affect family members with similar congenital deformities. To the best of our knowledge, the genetic factors predisposing to familial SWS have previously been unknown; however, systematic analysis of the genetic and molecular mechanisms underlying familial SWS is warranted.

GNAQ mutation R183Q as a potential cause of familial Sturge-Weber syndrome: A case report

ZHENGYI HUANG1*, YUCHI LI2*, ZENGXIA ZHAO3*, JUN HU1*, XIAOXIN TONG1, XUHUI CHEN1, SHUYUN LUI3, XIAONAN XU4, YONGJUN TAO5, TINGTING WANG6, XIN CHENG7, YANGYANG DAI8, YAOTING GUI2 and JUN WU1

1Department of Neurology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036;
2The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen Peking University and Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong 518036; 3Department of Neurology, The Shenzhen Longhua New District Central Hospital, Shenzhen, Guangdong 511180; 4Department of Neurology, Shenzhen Shekou People's Hospital, Shenzhen, Guangdong 518000; 5Department of Neurology, Taizhou Municipal Hospital, Taizhou, Zhejiang 318000; 6Shantou University Medical College, Shantou, Guangdong 515041; 7Anhui Medical University, Hefei, Anhui 230032; 8Guangzhou Medical University, Guangzhou, Guangdong 510182, P.R. China

Received August 27, 2015; Accepted December 6, 2016

DOI: 10.3892/ol.2017.5791
Case report

In the present study, a 4-generation family with a history of SWS was analyzed and demonstrated dominant inheritance of SWS (Fig. 1). SWS was diagnosed in 3 of the family members (II-1, III-11 and IV-6). The patients' clinicopathological characteristics are illustrated in Table I. The present study was reviewed and approved by the Ethics Committees of Peking University Shenzhen Hospital (Shenzhen, China) and informed consent was obtained from all patients. To systematically screen for candidate mutations associated with SWS, the full range of exons from the GNAQ and RASA1 genes of all family members were sequenced using Sanger sequencing Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The primer sequences of exons from the GNAQ and RASA1 genes are presented in Tables II and III.

To identify the candidate mutation, all the genetic variants common to the three patients with SWS were compared with the control data from family member IV-5 (Fig. 2). A total of 8 case-specific genetic variants that coexisted in the 3 patients were identified. The case-specific variants were subsequently compared with genetic polymorphism datasets from the Single Nucleotide Polymorphism database [National Center for Biotechnology Information (NCBI); http://www.ncbi.nlm.nih.gov/projects/SNP] and the 1000 Genome Project database (http://www.1000genomes.org/). Following these two comparative steps, a novel candidate mutation, potentially associated with familial SWS, was identified.

According to the NCBI (http://www.ncbi.nlm.nih.gov/), the human GNAQ gene is located on chromosome 9q21, and contains 7 exons and 8 introns, encoding guanine nucleotide-binding protein (G protein), q polypeptide (Gaq). As illustrated in Fig. 2, one non-synonymous single-nucleotide variation (nsSNV) was present exclusively in the 3 patients with SWS. The variation was predicted to be located on the fourth exon of GNAQ and resulted in the substitution of amino acid p.Arg183Gln (p.R183Q). Evolutionary conservation analysis was performed using MegAlign software version 5 (DNASTAR®, Madison, WI, USA). Multiple protein alignments revealed that the Arg183 residue on the GNAQ gene is highly conserved across several vertebrate species (Fig. 3), which indicates that the p.R183Q mutation is likely to disrupt the normal functions of Gaq. In addition, the functional significance of the SWS-associated mutation was predicted using several complementary nsSNV scoring algorithms, including SIFT (5), PolyPhen2 (6), PhastCons (7) and GERP scores (8). As hypothesized, the p.R183Q mutation results in a change to the function of the encoded protein Gaq.

To detect the sub-cellular localization of Gaq, the mutant (R183Q) and wild-type (WT) genotypes of the human GNAQ gene were overexpressed in 293T cells. The cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The coding sequence of human GNAQ (WT) was amplified using reverse transcription-polymerase chain reaction (RT-PCR) analysis with the following primers: Forward, 5'-CCGGGATCCATGACTCGGAGTCCATCATGCGGCT-3' and reverse, 5'-CCGGGATCCACGCCATGAGTGGACTCAGAGTCAT-3'. Reverse transcription was performed using a PrimeScript™ Reverse Transcription Reagent kit (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's protocol. The thermocycling conditions were as follows: 37°C for 60 min; 95°C for 5 min; and then held at 4°C. PCR was performed using the Takara EmeraldAmp PCR Master mix (Takara Biotechnology Co., Ltd.). The PCR thermocycling conditions were as follows: 98°C for 2 min, 98°C for 20 sec, 60°C for 30 sec and 72°C for 2 min for 36 cycles, with a final step at 72°C for 5 min. Subsequently, the PCR products were double-digested at 37°C for 60 min using the restriction endonucleases EcoRI and BamHI (Takara Bio, Inc., Otsu, Japan), and the digested products were sub-cloned into the plasmid enhanced green fluorescent protein (EGFP)-C1 vector (Thermo Fisher Scientific, Inc.) to produce a pEGFP-C1-GNAQ fusion protein-expressing vector. The coding sequence of EGFP-GNAQ was confirmed through DNA sequencing by Thermo Fisher Scientific, Inc. The GNAQ mutant was synthesized by Thermo Fisher Scientific, Inc. The GNAQ gene was cloned into the pEGFP-N1 vector and co-transfected into 293T cells. The data showed that the GNAQ (WT) recombinant protein was predominantly detected in the cytoplasm, whereas the GNAQ (R183Q) was mainly detected in the nuclei of 293T cells (Fig. 4). This result suggests that the change of subcellular localization contributes to the generation of a loss-of-function Gaq protein. The results of the present study demonstrated that the mutation p.R183Q may be a risk factor that contributes to the pathogenesis of familial SWS.

Discussion

Gaq is a member of the q class of G-protein α subunits that mediates signals between G protein-coupled receptors (GPCRs) and downstream effectors. GPCRs are involved in RAS-associated signaling pathways. Gaq Arg183 is conserved in the GTP-binding pocket of all human Gα subunits, which serves an essential role in the hydrolysis of GTP. Results from previous studies have demonstrated that substituting Arg183 with a cysteine residue reduces the intrinsic GTPase activity and increases the signaling activity (10-12). The p.R183Q mutation identified in the present study is located in the GTP-binding domain of GNAQ. Therefore, it was hypothesized that the substitution of arginine with glutamine affects the functions of Gaq by changing its subcellular localization.

Previous studies have established that activating mutations in genes that encode Gα subunits are associated with various diseases, including McCune-Albright syndrome,
which exhibits characteristic skeletal abnormalities and abnormal skin pigmentation (13). Activating GNAQ mutations have been found in patients with blue nevi and nevi of Ota (14). In addition, GNAQ mutations were previously identified in a chemical mutagenesis screen for a dark-skin phenotype in laboratory mice (15). An activating GNAQ mutation may have oncogenic functions (16). The results of several studies revealed that mutations in the Q209 and R183 residues of the GNAQ gene, including the Q209L substitution located in the Ras-like domain, are likely to exhibit involvement in the process of tumorigenesis via the upregulation of the mitogen-activated protein kinase pathway (16). R183 is located in the GTP-binding pocket of the Gα subunit and has an important role in GTP hydrolysis; however, a markedly lower potential to activate signal transmission was found for the R183 mutant compared with the Q209 mutant (17,18).

In the current study, the R183Q mutation of the GNAQ gene was identified as a potential cause for familial SWS through the sequencing of all of the exons of the GNAQ and RASA1 genes in 3 patients with familial SWS. The functional study confirmed that the genetic mutation R183Q affected the functions of the encoded protein, Gαq. To the best of our knowledge, the R183Q mutation is the first reported activating mutation in the GNAQ gene that affects familial SWS.

### Table I. Clinicopathological characteristics of the 3 patients with SWS from the 4-generation family.

| Family member | Gender | Age, years | Presence of SWS | Location | Size, cm |
|---------------|--------|------------|-----------------|----------|---------|
| I-1           | M      | 74         | No              |          |         |
| I-2           | F      | 68         | No              |          |         |
| I-3           | M      | 73         | No              |          |         |
| I-4           | F      | 70         | No              |          |         |
| II-1          | M      | 52         | Yes             | Right arm| 2       |
| II-2          | F      | 48         | No              |          |         |
| III-1         | M      | 51         | No              |          |         |
| III-2         | F      | 55         | No              |          |         |
| III-3         | M      | 39         | No              |          |         |
| III-4         | F      | 42         | No              |          |         |
| III-5         | M      | 36         | No              |          |         |
| III-6         | F      | 37         | No              |          |         |
| III-7         | M      | 36         | No              |          |         |
| III-8         | F      | 38         | No              |          |         |
| III-9         | M      | 37         | Yes             | Left arm | 2       |
| III-10        | F      | 35         | No              |          |         |
| III-11        | M      | 37         | Yes             | Left arm | 2       |
| III-12        | F      | 38         | No              |          |         |
| IV-1          | M      | 24         | No              |          |         |
| IV-2          | M      | 12         | No              |          |         |
| IV-3          | M      | 10         | No              |          |         |
| IV-4          | F      | 8          | No              |          |         |
| IV-5          | M      | 8          | No              |          |         |
| IV-6          | M      | 7          | Yes             | Right face| 4      |

SWS, Sturge-Weber syndrome; M, male; F, female.

### Table II. Primer sequences for reverse transcription-polymerase chain reaction amplification of G protein subunit αq exons.

| Exon | Forward primer sequence (5'-3') | Reverse primer sequence (5'-3') | Size, bp |
|------|--------------------------------|--------------------------------|----------|
| 1    | AGACTATCCGCTCCCACCCGC           | GCCTCTGGTCGGAGTGATCTGC          | 694      |
| 2    | CATAGGTAGTAGTTTCAATCTTAGA        | ATGATACTTTACAAACTCTCCTTA        | 660      |
| 3    | AAGGAAGGTTGTTACCTGAATTTGA       | TTAGATTTATGAGTTGGCATATGAG       | 420      |
| 4    | ATGTAATCCATAGATGGATAACCTT       | TTGTTTTGAAGCCTACACATGATT        | 430      |
| 5    | GTATTAATTTGAATTGTGACTGTGGATGA   | TCAGAACCCTCTGCACTGTGA           | 514      |
| 6    | ATGACAGTGTTCCAGATTCCACACCAC    | ACACCCGGAATTTTTGGAGACAAAAAC     | 530      |
| 7    | TTCATGAGCAATGACACAGTATTT        | GACGGCAATAAAATAGTATTAGTGC       | 398      |
knowledge, this is the first genetic mutation to be associated with the pathogenesis of familial SWS. The results of the present study, in addition to data from previous studies, suggest that an imbalance in the hydrolysis of GTP is the common cause of certain congenital neurocutaneous disorders, such as SWS. These findings may aid in the development of novel diagnostic markers and/or therapeutic targets for the treatment of patients with familial SWS.

Table III. Primer sequences for reverse transcription-polymerase chain reaction amplification of RAS p21 protein activator 1 exons.

| Exon | Forward primer sequence (5'-3') | Reverse primer sequence (5'-3') | Size, bp |
|------|---------------------------------|---------------------------------|---------|
| 1    | GAGTAGAGCCGGGCTTCAACATGA       | GGAGCCAGCTTCCCAAAATCCTGA       | 600     |
| 2    | GGCATTTAACACTCTAGTGTAT         | TAAATATTTTGAGGATCAGCACAG       | 480     |
| 3    | TAGCCCCCAAGTTAATTTTACTGTGAT    | ATTTCAAGAATCTGTCAGCAAACTG      | 630     |
| 4    | GGCACCTGGGTATTTTATGCTCAAG      | GTGAGAGACATGGAATAAAACC         | 475     |
| 5    | ACTCTACTTCCTACATTTTTCTTAAT     | TTAAATATGTCGACCTGATGTTATG     | 420     |
| 6    | TTAAGAGAGAGTTGGAGAAGATATT      | GAGTAAGAGAGAATTTGGGATTAT      | 590     |
| 7    | AGACCTTAAAAGCTCTGTATTTATTCA    | TCACTCTGTGTTTACCTTGAG         | 590     |
| 8    | AAGCTGGTAAATACACAGCAAGA        | GACACTGTGCTAAGAATTCTTGGG       | 539     |
| 9    | CTGGATGTTGATGAGAAATCAGA        | AGGTTGTCTCAGTCTACAAATAAT       | 520     |
| 10   | CTTTGAGAAGAAAGATGTTTTTAATTA    | ATGCTTATATGTTGAGGCTTTACCAA    | 410     |
| 11   | AGGCATTCTTTGGATAGTTTGTGAT      | AAGTGCATCTGCTACTTTGGAAG        | 449     |
| 12   | ACTGATAACATTTTATTAGTCTGT       | AGGTCATATTTAAATGAGTTTTC        | 527     |
| 13   | TGAGAATAGAAATGGCCATCTAG        | TTTCTAAGAAGATGACCTTTCCTCT      | 360     |
| 14   | ATGTCTGAATGTTTTAAGATGTCTG      | GCTATTAGAAACCTGGATGTTAA        | 460     |
| 15   | GAGGTAAAAAGAGGTAGGAAAGA        | TAAACAGTGTGAGTACGTTAAGCAT      | 500     |
| 16   | CTCTCTACCTATGAGTTTATG          | GTGCTACTAAGCTATGGAATCTACT      | 480     |
| 17   | AATGATGCAGAGATTTTAACCT        | TTGTTGGCTCTAGTCTACTTCG         | 600     |
| 18   | CTTGTAATTTATGACTCTTTCAAGCG   | ATATTTCTGCGAACACTTGG          | 518     |
| 19   | GGCCTTAAAGGTTGAAATATAATGTTAAC | ACCATGATCTTTTTCTTACGTAATAATA  | 450     |
| 20   | ATAAAGTATTTCCCTACCCCTTGCT      | GCCTCATTGTGTAAGGTTAAA         | 519     |
| 21   | GGTGTAGAGTGATTTATGGTGGAAGA    | GTTGTGAGACACAATAGGGGTA         | 462     |
| 22   | AATTTCTGATTGCTCCAGAAGAGA      | CTTTCTCATGCTAAAATTTCTACGC      | 335     |
| 23   | TTGTTGGCTGCTCTAGCCTAAT        | AAGGCAGACAAAATTTTGCCAGG        | 400     |
| 24   | ATGTTGAACTACAAGGTTTAAAGCT     | CAGACTCAGACGACAAAACCTG         | 744     |
| 25   | GAATTGTTGGTAAATATTTTATGCTAC   | CAGATAGCTTACAAGGGTTGCT         | 395     |

Figure 2. A missense mutation in the G protein subunit αq gene identified in patients with familial SWS. Trace chromatograms were developed using Sanger sequencing and revealed a validated missense mutation (p.R183Q). The three upper panels illustrate the sequencing chromatograms of the patients with familial, SWS II-1, III-11 and IV-6, while the lower panel illustrates the sequencing chromatogram of the control group, IV-5. SWS, Sturge-Weber syndrome.

Figure 3. Evolutionary conservation analysis of amino acids affected by the missense mutation. The identification numbers of guanine nucleotide-binding protein (G protein), α polypeptide were as follows: Human (NP_002063.2), Chimpanzee (XP_003212167.1), Rhesus (XP_001100033.1), Bovine (NP_001103472.1), Rat (NP_112298.1) and Mouse (NP_032165.3). The mutant alleles are boxed, and the asterisk (*) shows the conserved residue.
Acknowledgements

The present study was supported by the Shenzhen Project of Science and Technology (grant no. 20130309175830). The experiments were performed at The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics (Peking University Shenzhen Hospital, Shenzhen, China).

References

1. Giannantoni NM, Della Marca G and Vollono C: An Apparently Classical Case Report of Sturge-Weber syndrome. Clin EEG Neurosci 46: 353-356, 2015.
2. Comi AM: Update on Sturge-Weber syndrome: Diagnosis, treatment, quantitative measures, and controversies. Lymphat Res Biol 5: 257-264, 2007.
3. Piram M, Lorette G, Sirinelli D, Herbreteau D, Giraudou B and Maruani A: Sturge-Weber syndrome in patients with facial port-wine stain. Pediatr Dermatol 29: 32-37, 2012.
4. Shirley MD, Tang H, Gallione CJ, Baughner JD, Frelin LP, Cohen B, North PE, Marchuk DA, Comi AM and Pevsner J: Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 368: 1971-1979, 2013.
5. Ng PC and Henikoff S: SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812-3814, 2003.
6. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS and Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249, 2010.
7. Blanchette M, Kent WJ, Riemer C, Elnitski L, Smit AF, Roskin KM, Baertsch R, Rosenbloom K, Clawson H, Green ED, et al: Aligning multiple genomic sequences with the threaded blockset aligner. Genome Res 14: 708-715, 2004.
8. Cooper GM, Goode DL, Ng SB, Sidow A, Bamshad MJ, Shendure J and Nickerson DA: Single-nucleotide evolutionary constraint scores highlight disease-causing mutations. Nat Methods 7: 250-251, 2010.
9. Wu S, Sun X, Zhu W, Huang Y, Mou L, Liu M, Li X, Li F, Li X, Zhang Y, et al: Evidence for GAL3ST4 mutation as the potential cause of pectus excavatum. Cell Res 22: 1712-1715, 2012.
10. Conklin BR, Chabre O, Wong YH, Federman AD and Bourne HR: Recombinant Gq alpha. Mutational activation and coupling to receptors and phospholipase C. J Biol Chem 267: 31-34, 1992.
11. Coleman DE, Berghuis AM, Lee E, Linder ME, Gilman AG and Sprang SR: Structures of active conformations of Gi alpha 1 and the mechanism of GTP hydrolysis. Science 265: 1405-1412, 1994.
12. Kimple AJ, Bosch DE, Giguerre PM and Siderovski DP: Regulators of G-protein signaling and their Galfa substrates: Promises and challenges in their use as drug discovery targets. Pharmacol Rev 63: 728-749, 2011.
13. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E and Spiegel AM: Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325: 1688-1695, 1991.
14. Van Raamsdonk CD, Bezrakovova V, Green G, Bauer J, Gaugler L, O’Brien JM, Simpson EM, Barsh GS and Bastian BC: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457: 599-602, 2009.
15. Van Raamsdonk CD, Fitch KR, Fuchs H, de Angelis MH and Barsh GS: Effects of G-protein mutations on skin color. Nat Genet 36: 961-968, 2004.
16. Nakashima M, Miyajima M, Sugano H, Iimura Y, Kato M, Tsurusaki Y, Miyake N, Saito H, Arai H and Matsumoto N: The somatic GNAQ mutation c.548G>A (p.R183Q) is consistently found in Sturge-Weber syndrome. J Hum Genet 59: 691-693, 2014.
17. Orth JH, Preuss J, Fester I, Schlosser A, Wilson BA and Aktories K: Pasteurella multocida toxin activation of heterotrimeric G proteins by deamidation. Proc Natl Acad Sci USA 106: 7179-7184, 2009.
18. O’Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S and Gutkind JS: The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer 13: 412-424, 2013.